Lupin has officially expanded its international operations by incorporating a new wholly owned subsidiary in Thailand. Named Lupin (Thailand) Limited, this new entity was established on April 17, 2026. The subsidiary will focus on the importation, marketing, and distribution of pharmaceutical products within the Thai market. This move marks a strategic step for the company in strengthening its presence in Southeast Asia and capturing new growth opportunities within the region’s healthcare sector.
Strategic Expansion into Thailand
On April 17, 2026, Lupin announced the successful incorporation of its newest subsidiary, Lupin (Thailand) Limited. As a wholly owned entity, this development aligns with the company’s long-term strategy to broaden its global footprint and enhance its direct reach into key emerging markets. By establishing a dedicated presence in Thailand, the company aims to streamline its supply chain and better serve the local demand for its pharmaceutical portfolio.
Business Objectives and Capital Structure
Lupin (Thailand) Limited is set to act as the core regional hub for importing, promoting, and distributing a wide array of pharmaceutical products. To facilitate these operations, the company has set a registered and paid-up capital of 3,000,000 Baht. The capital structure is comprised of 600,000 shares, each with a par value of 5 Baht. This investment underscores the company’s commitment to investing in high-potential markets to drive sustainable long-term growth.
Source: BSE
